These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37037091)

  • 1. Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications.
    Bashraheel SS; Kheraldine H; Khalaf S; Moustafa AA
    Biomed Pharmacother; 2023 Jun; 162():114676. PubMed ID: 37037091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and Breast Cancer: Molecular Targets.
    Faria J; Negalha G; Azevedo A; Martel F
    J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.
    Dutta S; Shah RB; Singhal S; Dutta SB; Bansal S; Sinha S; Haque M
    Drug Des Devel Ther; 2023; 17():1907-1932. PubMed ID: 37397787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action.
    Bang S; Chen Y; Ahima RS; Kim SF
    Mol Endocrinol; 2014 Jul; 28(7):1186-93. PubMed ID: 24877601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
    Cell Cycle; 2009 Jan; 8(1):88-96. PubMed ID: 19106626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions.
    Sekar AP; Nurmala S; Matsuura E; Tan XW; Rahmasari R; Sauriasari R
    Breast Cancer (Auckl); 2024; 18():11782234241240173. PubMed ID: 38779416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways.
    Ikhlas S; Ahmad M
    Life Sci; 2017 Sep; 185():53-62. PubMed ID: 28755883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
    Guppy A; Jamal-Hanjani M; Pickering L
    Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
    Jaromy M; Miller JD
    Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin is synthetically lethal with glucose withdrawal in cancer cells.
    Menendez JA; Oliveras-Ferraros C; Cufí S; Corominas-Faja B; Joven J; Martin-Castillo B; Vazquez-Martin A
    Cell Cycle; 2012 Aug; 11(15):2782-92. PubMed ID: 22809961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin as an Anticancer Agent.
    Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
    Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Martin-Castillo B; Menendez JA
    Curr Mol Med; 2010 Oct; 10(7):674-91. PubMed ID: 20712585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin: taking away the candy for cancer?
    Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
    Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.
    Chikermane SG; Sharma M; Abughosh SM; Aparasu RR; Trivedi MV; Johnson ML
    Breast Cancer Res Treat; 2022 Oct; 195(3):421-430. PubMed ID: 35969285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin: from mechanisms of action to therapies.
    Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
    Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
    He X; Esteva FJ; Ensor J; Hortobagyi GN; Lee MH; Yeung SC
    Ann Oncol; 2012 Jul; 23(7):1771-80. PubMed ID: 22112968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current understanding of metformin effect on the control of hyperglycemia in diabetes.
    An H; He L
    J Endocrinol; 2016 Mar; 228(3):R97-106. PubMed ID: 26743209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.
    Corominas-Faja B; Quirantes-Piné R; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Martin-Castillo B; Micol V; Joven J; Segura-Carretero A; Menendez JA
    Aging (Albany NY); 2012 Jul; 4(7):480-98. PubMed ID: 22837425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.